Cargando…

Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy

Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with huma...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Tomohiro, Kitayama, Hiromitsu, Sugiyama, Junko, Hirayama, Michiaki, Suzuki, Yoshinori, Oyamada, Yumiko, Tsuji, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228553/
https://www.ncbi.nlm.nih.gov/pubmed/28105352
http://dx.doi.org/10.3892/mco.2016.1058
_version_ 1782493969165320192
author Kondo, Tomohiro
Kitayama, Hiromitsu
Sugiyama, Junko
Hirayama, Michiaki
Suzuki, Yoshinori
Oyamada, Yumiko
Tsuji, Yasushi
author_facet Kondo, Tomohiro
Kitayama, Hiromitsu
Sugiyama, Junko
Hirayama, Michiaki
Suzuki, Yoshinori
Oyamada, Yumiko
Tsuji, Yasushi
author_sort Kondo, Tomohiro
collection PubMed
description Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with human epidermal growth factor receptor 2-positive gastric cancer with peritoneal, pulmonary and bilateral ovarian metastases. After 6 cycles of S-1 plus cisplatin with trastuzumab, followed by 15 cycles of intravenous and intraperitoneal paclitaxel with S-1 and trastuzumab, the pulmonary and peritoneal metastases exhibited complete response and no evidence of malignancy was found on diagnostic laparoscopy. We performed metastasectomy of the bilateral sizeable ovaries, followed by total gastrectomy. The patient had no recurrence for 16 months after the gastrectomy. Therefore, satisfactory response to systemic and intraperitoneal chemotherapy may convert unresectable to resectable disease, and primary tumor resection with ovarian metastasectomy may prolong survival. This combination chemotherapy has the potential of becoming a conversion therapy for gastric cancer with peritoneal metastases, even if ascites and ovarian metastases are extensive.
format Online
Article
Text
id pubmed-5228553
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-52285532017-01-19 Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy Kondo, Tomohiro Kitayama, Hiromitsu Sugiyama, Junko Hirayama, Michiaki Suzuki, Yoshinori Oyamada, Yumiko Tsuji, Yasushi Mol Clin Oncol Articles Intravenous and intraperitoneal paclitaxel with S-1 is showing promising results in gastric cancer with peritoneal metastases. We herein report a successful conversion of unresectable to resectable disease using combination chemotherapy with trastuzumab. The patient was a 39-year-old woman with human epidermal growth factor receptor 2-positive gastric cancer with peritoneal, pulmonary and bilateral ovarian metastases. After 6 cycles of S-1 plus cisplatin with trastuzumab, followed by 15 cycles of intravenous and intraperitoneal paclitaxel with S-1 and trastuzumab, the pulmonary and peritoneal metastases exhibited complete response and no evidence of malignancy was found on diagnostic laparoscopy. We performed metastasectomy of the bilateral sizeable ovaries, followed by total gastrectomy. The patient had no recurrence for 16 months after the gastrectomy. Therefore, satisfactory response to systemic and intraperitoneal chemotherapy may convert unresectable to resectable disease, and primary tumor resection with ovarian metastasectomy may prolong survival. This combination chemotherapy has the potential of becoming a conversion therapy for gastric cancer with peritoneal metastases, even if ascites and ovarian metastases are extensive. D.A. Spandidos 2016-12 2016-10-21 /pmc/articles/PMC5228553/ /pubmed/28105352 http://dx.doi.org/10.3892/mco.2016.1058 Text en Copyright: © Kondo et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Kondo, Tomohiro
Kitayama, Hiromitsu
Sugiyama, Junko
Hirayama, Michiaki
Suzuki, Yoshinori
Oyamada, Yumiko
Tsuji, Yasushi
Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title_full Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title_fullStr Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title_full_unstemmed Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title_short Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
title_sort conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5228553/
https://www.ncbi.nlm.nih.gov/pubmed/28105352
http://dx.doi.org/10.3892/mco.2016.1058
work_keys_str_mv AT kondotomohiro conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT kitayamahiromitsu conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT sugiyamajunko conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT hirayamamichiaki conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT suzukiyoshinori conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT oyamadayumiko conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy
AT tsujiyasushi conversiontherapyofgastriccancerwithmassivemalignantascitesandovarianmetastasesbysystemicandintraperitonealchemotherapy